Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the maximum tolerated dose of the combination of two
drugs. The two drugs are Sorafenib and Capecitabine. The drug Sorafenib is an approved drug
which is used to treat certain cancers. The drug Capecitabine is approved to treat patients
with advanced breast cancer as well as early stage colon cancer.